<p>RNS 编号：1211N 摩根士丹利公司 2025 年 12 月 30 日</p>
<p>表格 38.5(a) (EPT/RI)</p>
<p>爱尔兰收购委员会</p>
<p>根据爱尔兰收购委员会规则 38.5(a) 的交易披露</p>
<p>《爱尔兰收购委员会法案，1997 年，收购规则，2022 年》</p>
<p>由具有认可中介身份的关联豁免主要交易者进行</p>
<p>并以客户服务的身份进行交易</p>
<ol>
<li>关键信息</li>
</ol>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) 豁免主要交易者名称：</td>
<td>摩根士丹利公司</td>
</tr>
<tr>
<td>(b) 与本表相关的要约方/被要约方名称：<br/>每个要约方/被要约方使用单独的表格</td>
<td>Avadel Pharmaceuticals plc</td>
</tr>
<tr>
<td>(c) 与豁免主要交易者相关的要约方名称：(注 1)</td>
<td>Avadel Pharmaceuticals plc</td>
</tr>
<tr>
<td>(d) 进行交易的日期：</td>
<td>2025 年 12 月 29 日</td>
</tr>
<tr>
<td>(e) 除上述 1(b) 中的公司外，豁免主要交易者是否还在披露任何其他要约方的信息？<br/>如果是现金要约或可能的现金要约，请说明 “N/A”</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<ol>
<li>豁免主要交易者的交易（注 2）</li>
</ol>
<p>如果在 1(b) 中提到的要约方或被要约方的相关证券中有多个类别的交易，请为每个额外的相关证券类别复制表 2(a)、(b)、(c) 或 (d)（视情况而定）。</p>
<p>所有价格和其他货币金额的货币应予以说明。</p>
<p>(a) 购买和销售</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别<br/>(注 3)</td>
<td>购买/ <br/>销售</td>
<td>证券总数</td>
<td>每单位支付/ <br/>收到的最高价格</td>
<td>每单位支付/ <br/>收到的最低价格</td>
</tr>
<tr>
<td>0.01 普通股</td>
<td>购买</td>
<td>103,070</td>
<td>21.5775 美元</td>
<td>21.5110 美元</td>
</tr>
<tr>
<td>0.01 普通股</td>
<td>销售</td>
<td>103,374</td>
<td>21.5700 美元</td>
<td>21.5100 美元</td>
</tr>
</tbody>
</table>
<p>(b) 现金结算衍生品交易</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>N/A</td>
</tr>
<tr>
<td>产品描述<br/>例如 CFD</td>
<td>N/A</td>
</tr>
<tr>
<td>交易性质<br/>例如开仓/平仓<br/>多头/空头头寸，<br/>增加/减少<br/>多头/空头头寸</td>
<td>N/A</td>
</tr>
<tr>
<td>参考证券数量<br/>(注 4)</td>
<td>N/A</td>
</tr>
<tr>
<td>每单位价格<br/>(注 5)</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<p>(c) 股票结算衍生品交易（包括期权）</p>
<p>(i) 写入、出售、购买或变更</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>N/A</td>
</tr>
<tr>
<td>产品描述<br/>例如看涨期权</td>
<td>N/A</td>
</tr>
<tr>
<td>写入、<br/>购买、<br/>出售、<br/>变更等</td>
<td>N/A</td>
</tr>
<tr>
<td>相关期权的<br/>证券数量<br/>(注 4)</td>
<td>N/A</td>
</tr>
<tr>
<td>每单位行使价格</td>
<td>N/A</td>
</tr>
<tr>
<td>类型<br/>例如<br/>美式、<br/>欧式<br/>等</td>
<td>N/A</td>
</tr>
<tr>
<td>到期日期</td>
<td>N/A</td>
</tr>
<tr>
<td>每单位支付/收到的期权金</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<p>(ii) 行使</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>N/A</td>
</tr>
<tr>
<td>产品描述<br/>例如看涨期权</td>
<td>N/A</td>
</tr>
<tr>
<td>行使/已行使<br/>对</td>
<td>N/A</td>
</tr>
<tr>
<td>证券数量</td>
<td>N/A</td>
</tr>
<tr>
<td>每单位行使价格<br/>(注 5)</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<p>(d) 其他交易（包括新证券的交易）</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>N/A</td>
</tr>
<tr>
<td>交易性质<br/>例如认购、<br/>转换、<br/>行使</td>
<td>N/A</td>
</tr>
<tr>
<td>详情</td>
<td>N/A</td>
</tr>
<tr>
<td>每单位价格<br/>(如适用)<br/>(注 5)</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<ol>
<li>其他信息</li>
</ol>
<p>(a) 赔偿和其他交易安排</p>
<ul>
<li>任何赔偿或期权安排的详细信息，或与相关证券有关的任何协议或理解，无论是正式还是非正式，可能会诱使豁免主要交易者进行或避免进行交易，与要约方或与要约方协同行动的任何人之间达成的协议：不可撤销的承诺和意向书不应包括。如果没有此类协议、安排或理解，请说明 “无”</li>
<li>无</li>
</ul>
<p>(b) 与期权或衍生品相关的协议、安排或理解</p>
<ul>
<li>披露人和任何其他人之间与本表中提到的任何期权下的相关证券投票权或与本表中提到的任何衍生品相关的相关证券的未来收购或处置的投票权的任何协议、安排或理解的完整细节。如果没有，应予以说明。</li>
<li>无</li>
</ul>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>披露日期：</td>
<td>2025 年 12 月 30 日</td>
</tr>
<tr>
<td>联系人姓名：</td>
<td>Claire Gordon</td>
</tr>
<tr>
<td>电话号码：</td>
<td>+44 141 245-8893</td>
</tr>
</tbody>
</table>
<p>根据规则 38 的规定，公共披露必须向监管信息服务进行。</p>
<p>此信息由 RNS 提供，RNS 是伦敦证券交易所的新闻服务。RNS 获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。</p>
<p>RNS 可能会使用您的 IP 地址以确认遵守条款和条件，分析您与本通信中包含的信息的互动，并在匿名基础上与他人分享此分析，作为我们商业服务的一部分。如需更多关于 RNS 和伦敦证券交易所如何使用您提供的个人数据的信息，请参见我们的隐私政策。结束 ITPTMBRTMTIJMFA</p>

摩根士丹利

Avadel制药

<p>摩根士丹利公司披露了与 Avadel Pharmaceuticals plc 相关的交易，依据爱尔兰收购委员会第 38.5(a) 条款。2025 年 12 月 29 日，该公司以 21.51 美元至 21.57 美元的价格购买了 103,070 股普通股，并以类似价格出售了 103,374 股。没有报告其他交易或协议。该披露由 Claire Gordon 于 2025 年 12 月 30 日发布，并提供了进一步咨询的联系方式</p>

<p>RNS Number : 1211N Morgan Stanley &amp; Co. LLC 30 December 2025</p>
<div class="lb-trans"><p>RNS 编号：1211N 摩根士丹利公司 2025 年 12 月 30 日</p>
</div><p>FORM 38.5(a) (EPT/RI)</p>
<div class="lb-trans"><p>表格 38.5(a) (EPT/RI)</p>
</div><p>IRISH TAKEOVER PANEL</p>
<div class="lb-trans"><p>爱尔兰收购委员会</p>
</div><p>DEALING DISCLOSURE UNDER RULE 38.5(a) OF THE IRISH</p>
<div class="lb-trans"><p>根据爱尔兰收购委员会规则 38.5(a) 的交易披露</p>
</div><p>TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022</p>
<div class="lb-trans"><p>《爱尔兰收购委员会法案，1997 年，收购规则，2022 年》</p>
</div><p>BY A CONNECTED EXEMPT PRINCIPAL TRADER WITH</p>
<div class="lb-trans"><p>由具有认可中介身份的关联豁免主要交易者进行</p>
</div><p>RECOGNISED INTERMEDIARY STATUS AND DEALING IN</p>
<div class="lb-trans"><p>并以客户服务的身份进行交易</p>
</div><p>A CLIENT-SERVING CAPACITY</p>
<p>1. KEY INFORMATION</p>
<div class="lb-trans"><ol>
<li>关键信息</li>
</ol>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) Name of exempt principal trader:</td>
<td>Morgan Stanley &amp; Co. LLC</td>
</tr>
<tr>
<td>(b) Name of offeror/offeree in relation to whose relevant securities this form relates:<br/>Use a separate form for each offeror/offeree</td>
<td>Avadel Pharmaceuticals plc</td>
</tr>
<tr>
<td>(c) Name of the party to the offer with which exempt principal trader is connected: (Note 1)</td>
<td>Avadel Pharmaceuticals plc</td>
</tr>
<tr>
<td>(d) Date dealing undertaken:</td>
<td>29 December 2025</td>
</tr>
<tr>
<td>(e) In addition to the company in 1(b) above, is the exempt principal trader also making disclosures in respect of any other party to the offer?<br/>If it is a cash offer or possible cash offer, state &#34;N/A&#34;</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) 豁免主要交易者名称：</td>
<td>摩根士丹利公司</td>
</tr>
<tr>
<td>(b) 与本表相关的要约方/被要约方名称：<br/>每个要约方/被要约方使用单独的表格</td>
<td>Avadel Pharmaceuticals plc</td>
</tr>
<tr>
<td>(c) 与豁免主要交易者相关的要约方名称：(注 1)</td>
<td>Avadel Pharmaceuticals plc</td>
</tr>
<tr>
<td>(d) 进行交易的日期：</td>
<td>2025 年 12 月 29 日</td>
</tr>
<tr>
<td>(e) 除上述 1(b) 中的公司外，豁免主要交易者是否还在披露任何其他要约方的信息？<br/>如果是现金要约或可能的现金要约，请说明 “N/A”</td>
<td>N/A</td>
</tr>
</tbody>
</table>
</div><p>2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER (Note 2)</p>
<div class="lb-trans"><ol>
<li>豁免主要交易者的交易（注 2）</li>
</ol>
</div><p>Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.</p>
<div class="lb-trans"><p>如果在 1(b) 中提到的要约方或被要约方的相关证券中有多个类别的交易，请为每个额外的相关证券类别复制表 2(a)、(b)、(c) 或 (d)（视情况而定）。</p>
</div><p>The currency of all prices and other monetary amounts should be stated.</p>
<div class="lb-trans"><p>所有价格和其他货币金额的货币应予以说明。</p>
</div><p>(a) Purchases and sales</p>
<div class="lb-trans"><p>(a) 购买和销售</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of <br/>relevant <br/>security <br/>(Note 3)</td>
<td>Purchases/ <br/>sales</td>
<td>Total<br/>number of <br/>securities</td>
<td>Highest <br/>price per <br/>unit paid/ <br/>received</td>
<td>Lowest <br/>price per <br/>unit paid/ <br/>received</td>
</tr>
<tr>
<td>0.01 ordinary shares</td>
<td>PURCHASES</td>
<td>103,070</td>
<td>21.5775 USD</td>
<td>21.5110 USD</td>
</tr>
<tr>
<td>0.01 ordinary shares</td>
<td>SALES</td>
<td>103,374</td>
<td>21.5700 USD</td>
<td>21.5100 USD</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别<br/>(注 3)</td>
<td>购买/ <br/>销售</td>
<td>证券总数</td>
<td>每单位支付/ <br/>收到的最高价格</td>
<td>每单位支付/ <br/>收到的最低价格</td>
</tr>
<tr>
<td>0.01 普通股</td>
<td>购买</td>
<td>103,070</td>
<td>21.5775 美元</td>
<td>21.5110 美元</td>
</tr>
<tr>
<td>0.01 普通股</td>
<td>销售</td>
<td>103,374</td>
<td>21.5700 美元</td>
<td>21.5100 美元</td>
</tr>
</tbody>
</table>
</div><p>(b) Cash-settled derivative transactions</p>
<div class="lb-trans"><p>(b) 现金结算衍生品交易</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of <br/>relevant <br/>security</td>
<td>N/A</td>
</tr>
<tr>
<td>Product <br/>description<br/>e.g. CFD</td>
<td>N/A</td>
</tr>
<tr>
<td>Nature of dealing <br/>e.g. opening/closing <br/>a long/short position, <br/>increasing/reducing a <br/>long/short position</td>
<td>N/A</td>
</tr>
<tr>
<td>Number of <br/>reference <br/>securities<br/>(Note 4)</td>
<td>N/A</td>
</tr>
<tr>
<td>Price per<br/>unit (Note 5)</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>N/A</td>
</tr>
<tr>
<td>产品描述<br/>例如 CFD</td>
<td>N/A</td>
</tr>
<tr>
<td>交易性质<br/>例如开仓/平仓<br/>多头/空头头寸，<br/>增加/减少<br/>多头/空头头寸</td>
<td>N/A</td>
</tr>
<tr>
<td>参考证券数量<br/>(注 4)</td>
<td>N/A</td>
</tr>
<tr>
<td>每单位价格<br/>(注 5)</td>
<td>N/A</td>
</tr>
</tbody>
</table>
</div><p>(c) Stock-settled derivative transactions (including options)</p>
<div class="lb-trans"><p>(c) 股票结算衍生品交易（包括期权）</p>
</div><p>(i) Writing, selling, purchasing or varying</p>
<div class="lb-trans"><p>(i) 写入、出售、购买或变更</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of <br/>relevant <br/>security</td>
<td>N/A</td>
</tr>
<tr>
<td>Product <br/>description<br/>e.g. call option</td>
<td>N/A</td>
</tr>
<tr>
<td>Writing, <br/>purchasing, <br/>selling, <br/>varying etc.</td>
<td>N/A</td>
</tr>
<tr>
<td>Number <br/>of <br/>securities <br/>to which <br/>option <br/>relates <br/>(Note 4)</td>
<td>N/A</td>
</tr>
<tr>
<td>Exercise <br/>price per <br/>unit</td>
<td>N/A</td>
</tr>
<tr>
<td>Type<br/>e.g. <br/>American, <br/>European <br/>etc.</td>
<td>N/A</td>
</tr>
<tr>
<td>Expiry<br/>date</td>
<td>N/A</td>
</tr>
<tr>
<td>Option <br/>money <br/>paid/ <br/>received <br/>per unit</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>N/A</td>
</tr>
<tr>
<td>产品描述<br/>例如看涨期权</td>
<td>N/A</td>
</tr>
<tr>
<td>写入、<br/>购买、<br/>出售、<br/>变更等</td>
<td>N/A</td>
</tr>
<tr>
<td>相关期权的<br/>证券数量<br/>(注 4)</td>
<td>N/A</td>
</tr>
<tr>
<td>每单位行使价格</td>
<td>N/A</td>
</tr>
<tr>
<td>类型<br/>例如<br/>美式、<br/>欧式<br/>等</td>
<td>N/A</td>
</tr>
<tr>
<td>到期日期</td>
<td>N/A</td>
</tr>
<tr>
<td>每单位支付/收到的期权金</td>
<td>N/A</td>
</tr>
</tbody>
</table>
</div><p>(ii) Exercise</p>
<div class="lb-trans"><p>(ii) 行使</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of <br/>relevant <br/>security</td>
<td>N/A</td>
</tr>
<tr>
<td>Product <br/>description <br/>e.g. call option</td>
<td>N/A</td>
</tr>
<tr>
<td>Exercising/ <br/>exercised <br/>against</td>
<td>N/A</td>
</tr>
<tr>
<td>Number of <br/>securities</td>
<td>N/A</td>
</tr>
<tr>
<td>Exercise price<br/>per unit<br/>(Note 5)</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>N/A</td>
</tr>
<tr>
<td>产品描述<br/>例如看涨期权</td>
<td>N/A</td>
</tr>
<tr>
<td>行使/已行使<br/>对</td>
<td>N/A</td>
</tr>
<tr>
<td>证券数量</td>
<td>N/A</td>
</tr>
<tr>
<td>每单位行使价格<br/>(注 5)</td>
<td>N/A</td>
</tr>
</tbody>
</table>
</div><p>(d) Other dealings (including transactions in respect of new securities)</p>
<div class="lb-trans"><p>(d) 其他交易（包括新证券的交易）</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of relevant security</td>
<td>N/A</td>
</tr>
<tr>
<td>Nature of <br/>dealing <br/>e.g. subscription, <br/>conversion, <br/>exercise</td>
<td>N/A</td>
</tr>
<tr>
<td>Details</td>
<td>N/A</td>
</tr>
<tr>
<td>Price per unit <br/>(if applicable) <br/>(Note 5)</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>N/A</td>
</tr>
<tr>
<td>交易性质<br/>例如认购、<br/>转换、<br/>行使</td>
<td>N/A</td>
</tr>
<tr>
<td>详情</td>
<td>N/A</td>
</tr>
<tr>
<td>每单位价格<br/>(如适用)<br/>(注 5)</td>
<td>N/A</td>
</tr>
</tbody>
</table>
</div><p>3. OTHER INFORMATION</p>
<div class="lb-trans"><ol>
<li>其他信息</li>
</ol>
</div><p>(a) Indemnity and other dealing arrangements</p>
<div class="lb-trans"><p>(a) 赔偿和其他交易安排</p>
</div><ul>
<li>Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state &#34;none&#34;</li>
<li>NONE</li>
</ul>
<div class="lb-trans"><ul>
<li>任何赔偿或期权安排的详细信息，或与相关证券有关的任何协议或理解，无论是正式还是非正式，可能会诱使豁免主要交易者进行或避免进行交易，与要约方或与要约方协同行动的任何人之间达成的协议：不可撤销的承诺和意向书不应包括。如果没有此类协议、安排或理解，请说明 “无”</li>
<li>无</li>
</ul>
</div><p>(b) Agreements, arrangements or understandings relating to options or derivatives</p>
<div class="lb-trans"><p>(b) 与期权或衍生品相关的协议、安排或理解</p>
</div><ul>
<li>Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.</li>
<li>NONE</li>
</ul>
<div class="lb-trans"><ul>
<li>披露人和任何其他人之间与本表中提到的任何期权下的相关证券投票权或与本表中提到的任何衍生品相关的相关证券的未来收购或处置的投票权的任何协议、安排或理解的完整细节。如果没有，应予以说明。</li>
<li>无</li>
</ul>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of disclosure:</td>
<td>30 December 2025</td>
</tr>
<tr>
<td>Contact name:</td>
<td>Claire Gordon</td>
</tr>
<tr>
<td>Telephone number:</td>
<td>+44 141 245-8893</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>披露日期：</td>
<td>2025 年 12 月 30 日</td>
</tr>
<tr>
<td>联系人姓名：</td>
<td>Claire Gordon</td>
</tr>
<tr>
<td>电话号码：</td>
<td>+44 141 245-8893</td>
</tr>
</tbody>
</table>
</div><p>Public disclosures under Rule 38 of the Rules must be made to a Regulatory Information Service.</p>
<div class="lb-trans"><p>根据规则 38 的规定，公共披露必须向监管信息服务进行。</p>
</div><p>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</p>
<div class="lb-trans"><p>此信息由 RNS 提供，RNS 是伦敦证券交易所的新闻服务。RNS 获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。</p>
</div><p>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ITPTMBRTMTIJMFA</p>
<div class="lb-trans"><p>RNS 可能会使用您的 IP 地址以确认遵守条款和条件，分析您与本通信中包含的信息的互动，并在匿名基础上与他人分享此分析，作为我们商业服务的一部分。如需更多关于 RNS 和伦敦证券交易所如何使用您提供的个人数据的信息，请参见我们的隐私政策。结束 ITPTMBRTMTIJMFA</p>
</div>

摩根士丹利&CoLLC Avadel 制药公司 - 规则 38.5_A - Avadel 制药公司